DK1242060T3 - Behandling af metastatisk sygdom - Google Patents
Behandling af metastatisk sygdomInfo
- Publication number
- DK1242060T3 DK1242060T3 DK00955687T DK00955687T DK1242060T3 DK 1242060 T3 DK1242060 T3 DK 1242060T3 DK 00955687 T DK00955687 T DK 00955687T DK 00955687 T DK00955687 T DK 00955687T DK 1242060 T3 DK1242060 T3 DK 1242060T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- metastatic disease
- compounds
- metastatic
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14925899P | 1999-08-17 | 1999-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1242060T3 true DK1242060T3 (da) | 2006-08-21 |
Family
ID=22529456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00955687T DK1242060T3 (da) | 1999-08-17 | 2000-08-17 | Behandling af metastatisk sygdom |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP2289940A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2003516930A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE324877T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU6784400A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2380888A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60027768T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1242060T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2261230T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1242060E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001012172A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| DZ3332A1 (fr) | 2000-03-31 | 2001-10-11 | Purdue Research Foundation | Methode de traitement a l'aide de conjugues ligand-immunogene |
| US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
| NZ537458A (en) * | 2001-01-23 | 2007-02-23 | Primagen Holding B | Means and methods for treatment evaluation |
| EP1225233A3 (en) * | 2001-01-23 | 2003-01-08 | Amsterdam Support Diagnostics B.V. | Means and methods for treatment evaluation |
| EP1298221A1 (en) * | 2001-09-28 | 2003-04-02 | PrimaGen Holding B.V. | Means and methods for treatment evaluation |
| DE60234782D1 (de) * | 2001-09-28 | 2010-01-28 | Purdue Research Foundation | Behandlungsverfahren mit liganden-immunogenkonjugaten |
| AU2003215190A1 (en) * | 2002-02-15 | 2003-09-09 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
| EP1519956B1 (en) * | 2002-05-10 | 2011-09-21 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| EP1575509B1 (en) * | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| EP1505999A4 (en) | 2002-05-23 | 2009-07-08 | Purdue Research Foundation | LOW-MOLECULAR PROTEIN-TYROSINE PHOSPHATASE (LMW-PTP) AS DIAGNOSTIC AND THERAPEUTIC TARGET |
| AU2004210463B2 (en) * | 2003-02-07 | 2009-07-16 | Ludwig Institute For Cancer Research Limited | Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis |
| AU2003900541A0 (en) * | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
| EP1617864A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING |
| EP1618184A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION |
| CA2525929A1 (en) | 2003-05-13 | 2004-11-25 | Chiron Corporation | Methods of modulating metastasis and skeletal related events resulting from metastases |
| WO2005016381A2 (en) * | 2003-07-21 | 2005-02-24 | Medimmune, Inc. | Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah |
| KR20060135671A (ko) * | 2003-11-20 | 2006-12-29 | 메디뮨 인코포레이티드 | EphA2 작동성 모노클로날 항체 및 이의 사용 방법 |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| AU2005277641A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| BRPI0607450A2 (pt) | 2005-02-04 | 2009-09-01 | Raven Biotechnologies Inc | anticorpos que se ligam a epha2 e métodos para sua utilização |
| WO2007092299A2 (en) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Targeted conjugates and radiation |
| ZA200900545B (en) * | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
| AU2007342333B2 (en) | 2006-09-12 | 2013-02-28 | Alphavax, Inc. | Alphavirus replicon particles encoding IL- 12 as immunological adjuvants |
| US20090022760A1 (en) | 2006-09-12 | 2009-01-22 | Alphavax | Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants |
| US20090047255A1 (en) | 2006-11-03 | 2009-02-19 | Alphavax, Inc. | Alphavirus and Alphavirus Replicon Particle Formulations and Methods |
| WO2009028639A1 (ja) * | 2007-08-30 | 2009-03-05 | Daiichi Sankyo Company, Limited | 抗epha2抗体 |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
| WO2018034332A1 (ja) * | 2016-08-19 | 2018-02-22 | 国立大学法人東京大学 | EphA2 N末端フラグメント抗体 |
| US20210268098A1 (en) | 2018-08-03 | 2021-09-02 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993003741A1 (en) | 1991-08-22 | 1993-03-04 | Becton, Dickinson & Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| CA2103323A1 (en) * | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| ES2242437T3 (es) * | 1998-11-20 | 2005-11-01 | Genentech, Inc. | Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares. |
-
2000
- 2000-08-17 EP EP10010861A patent/EP2289940A3/en not_active Withdrawn
- 2000-08-17 ES ES00955687T patent/ES2261230T3/es not_active Expired - Lifetime
- 2000-08-17 AU AU67844/00A patent/AU6784400A/en not_active Abandoned
- 2000-08-17 DE DE60027768T patent/DE60027768T2/de not_active Revoked
- 2000-08-17 WO PCT/US2000/022670 patent/WO2001012172A1/en not_active Ceased
- 2000-08-17 CA CA002380888A patent/CA2380888A1/en not_active Abandoned
- 2000-08-17 JP JP2001516518A patent/JP2003516930A/ja active Pending
- 2000-08-17 DK DK00955687T patent/DK1242060T3/da active
- 2000-08-17 AT AT00955687T patent/ATE324877T1/de not_active IP Right Cessation
- 2000-08-17 EP EP00955687A patent/EP1242060B1/en not_active Revoked
- 2000-08-17 PT PT00955687T patent/PT1242060E/pt unknown
-
2007
- 2007-08-15 JP JP2007211840A patent/JP2007306938A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007306938A (ja) | 2007-11-29 |
| PT1242060E (pt) | 2006-08-31 |
| EP1242060A1 (en) | 2002-09-25 |
| WO2001012172B1 (en) | 2001-08-16 |
| WO2001012172A1 (en) | 2001-02-22 |
| DE60027768D1 (de) | 2006-06-08 |
| EP1242060B1 (en) | 2006-05-03 |
| ATE324877T1 (de) | 2006-06-15 |
| EP2289940A3 (en) | 2011-09-21 |
| AU6784400A (en) | 2001-03-13 |
| CA2380888A1 (en) | 2001-02-22 |
| DE60027768T2 (de) | 2007-04-05 |
| JP2003516930A (ja) | 2003-05-20 |
| EP1242060A4 (en) | 2003-09-24 |
| ES2261230T3 (es) | 2006-11-16 |
| EP2289940A2 (en) | 2011-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1242060E (pt) | Tratamento da doenca metastatica | |
| BR0108396A (pt) | Derivados de pirimidina-4-0na como inibidores de ldl-pla(2) | |
| TR200003514T2 (tr) | Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri | |
| EP1140840A4 (en) | -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS | |
| EE05481B1 (et) | Kinasoliini derivaadid kasvajate raviks | |
| BR9814361A (pt) | Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila | |
| BR0215360A (pt) | Derivados de indolina úteis como inibidores de proteìna quinase | |
| TR200200928T2 (tr) | 2-pirazolin-5-on terkipleri | |
| DK1189634T3 (da) | Behandling af prostatacancer med anti-ErbB2-antistoffer | |
| NO2010002I2 (no) | Toceranibfosfat. | |
| BR0316229A (pt) | Métodos de tratamento de câncer e métodos relacionados | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| DK1147089T3 (da) | Phenylphenanthridiner med PDE-IV-inhiberende virkning | |
| WO2004100947A3 (en) | Novel chemical compounds | |
| BR0207378A (pt) | Tratamento de câncer | |
| MY141144A (en) | 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | |
| JO2248B1 (en) | Pirazolobenzodiazepines | |
| TR200200260T2 (tr) | N-desmetilzopiklonlarının üretim ve kullanım yöntemleri | |
| SI1771474T1 (sl) | Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba | |
| TR200401316T4 (tr) | Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler | |
| DE60020595D1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
| CY1112031T1 (el) | Υποκατεστημενη 5-φαινυλο-3,6-διυδρο-2-οξο-6η-[1,3,4]θειαδιαζινη | |
| DE60033918D1 (de) | Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung | |
| ATE406155T1 (de) | Triptolid-prodrugs zur krebstherapie | |
| EA200800011A1 (ru) | Тиенопиримидиновые и тиенопиридиновые модуляторы киназы |